PMID- 19949901
OWN - NLM
STAT- MEDLINE
DCOM- 20110408
LR  - 20211020
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 27
IP  - 4
DP  - 2010 Dec
TI  - Antitumor effect of mSurvivinThr34-->Ala in murine colon carcinoma when 
      administered intravenously.
PG  - 1156-63
LID - 10.1007/s12032-009-9353-2 [doi]
AB  - Colorectal cancer is one of the most common cancers. Survivin is strongly 
      immunogenic in a fraction of colorectal cancer patients. The present study was 
      designed to determine whether full-length mouse Survivin dominant-negative mutant 
      SurvivinT34A has the antitumor activity in a murine colon carcinoma model. The 
      complex of cationic liposome (DOTAP/Chol) to plasmid pORF9-mSurvivin T34A was 
      administered intravenously in a mouse subcutaneous (S. C.) CT 26 tumor model. 
      Apoptotic cells and anti-angiogenesis were evaluated by fluorescent in situ TUNEL 
      assay and by immunohistochemistry with an antibody reactive to CD31, 
      respectively. A 4 h 51Cr release assay was performed to determine 
      Survivin-specific cytotoxicity. The adoptive transfer of CD8+ or CD4+ 
      T-lymphocytes assay was to further explore the roles of immune cell subsets. We 
      demonstrated the complex of cationic liposome (DOTAP/Chol) to plasmid 
      pORF9--mSurvivin T34A when administered intravenously induced an efficient 
      antitumor activity in a S. C. CT26 tumor model in mice. The main mechanism is 
      involved in three aspects: triggering the apoptosis of tumor cells, inhibiting 
      angiogenesis, and inducing Survivin-specific immune response. Our observations 
      may have potential implications for the further exploration of the treatment of 
      human colorectal cancer by intravenous delivery of dominant-negative mutant 
      Survivin T34A.
FAU - Li, Hong-xia
AU  - Li HX
AD  - Department of Gynecology and Obstetrics, Second West China Hospital, Sichuan 
      University, Chengdu, 610041, People's Republic of China.
FAU - Zhao, Xin-yu
AU  - Zhao XY
FAU - Wang, Lian
AU  - Wang L
FAU - Wang, Yong-sheng
AU  - Wang YS
FAU - Kan, Bin
AU  - Kan B
FAU - Xu, Jian-rong
AU  - Xu JR
FAU - Li, Jiong
AU  - Li J
FAU - Wen, Yan-Jun
AU  - Wen YJ
FAU - Peng, Xing-chen
AU  - Peng XC
FAU - Chen, Xiang
AU  - Chen X
FAU - Yan, Fei
AU  - Yan F
FAU - Ye, Bin
AU  - Ye B
FAU - Du, Xiao-bo
AU  - Du XB
FAU - Zhao, Ju-mei
AU  - Zhao JM
FAU - Yi, Tao
AU  - Yi T
FAU - Chen, Xian-cheng
AU  - Chen XC
FAU - Du, Xiao-xia
AU  - Du XX
FAU - Wei, Yu-quan
AU  - Wei YQ
FAU - Zhao, Xia
AU  - Zhao X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091201
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Birc5 protein, mouse)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Liposomes)
RN  - 0 (Repressor Proteins)
RN  - 0 (Survivin)
RN  - 2ZD004190S (Threonine)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Adoptive Transfer
MH  - Alanine/genetics
MH  - Animals
MH  - Apoptosis
MH  - Blotting, Western
MH  - CD4-Positive T-Lymphocytes/immunology/metabolism
MH  - CD8-Positive T-Lymphocytes/immunology/metabolism
MH  - Cell Adhesion
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Colonic Neoplasms/*genetics/immunology/*therapy
MH  - Female
MH  - *Genetic Therapy
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Inhibitor of Apoptosis Proteins/genetics/immunology/*metabolism
MH  - Injections, Intravenous
MH  - Liposomes
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Neovascularization, Pathologic/*prevention & control
MH  - Repressor Proteins/genetics/immunology/*metabolism
MH  - Survivin
MH  - Threonine/genetics
EDAT- 2009/12/02 06:00
MHDA- 2011/04/09 06:00
CRDT- 2009/12/02 06:00
PHST- 2009/07/03 00:00 [received]
PHST- 2009/10/27 00:00 [accepted]
PHST- 2009/12/02 06:00 [entrez]
PHST- 2009/12/02 06:00 [pubmed]
PHST- 2011/04/09 06:00 [medline]
AID - 10.1007/s12032-009-9353-2 [doi]
PST - ppublish
SO  - Med Oncol. 2010 Dec;27(4):1156-63. doi: 10.1007/s12032-009-9353-2. Epub 2009 Dec 
      1.